| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
Augmented blood pressure (BP) variability has been recently reported to be a cardiovascular risk factor, which could be a novel therapeutic target. The aims of the present study are to identify the roles of the hypotensive peptides of ANP, BNP and adrenomedullin in augmentation of BP variability and to clarify the underlying mechanisms and therapeutic methods for augmented variability. Animal experiments of the present study showed that rat continuously infused with angiotensin II was found to be a useful model of augmented BP variability, while suggesting angiotensin II as a factor involved in augmented BP variability. In the meantime, clinical study revealed the association between long-term BP variability and plasma levels of ANP and BNP in humans. Based on these findings, future study will be aimed to identify the detailed mechanisms and therapeutic agents for augmented BP variability by using this animal model.
|
